Few older adults are taking the recently cleared respiratory syncytial virus vaccines, according to new studies from the U.S. Centers for Disease Control and Prevention (CDC).
Just 9.8 percent of seniors in nursing homes have received one of the shots against the virus, known as RSV, one of the papers showed.
The study analyzed data provided by nursing homes certified by the Centers for Medicare & Medicaid Services.
According to the nursing home data, just 33 percent of seniors have taken a new COVID-19 vaccine, while about seven in 10 have taken an influenza vaccine this fall.
The data were current as of Dec. 10.
“Coverage with each of the three vaccines, especially updated ... COVID-19 and RSV vaccines, was low among nursing home residents,” authors of the study, which included CDC employees, wrote.
The CDC published the paper in its quasi-journal, Morbidity and Mortality Weekly, on Dec. 21.
Authors of the new paper speculated the low uptake of the RSV vaccines might stem from factors including “the relative recency of the recommendation, vaccine fatigue associated with the introduction of a fourth respiratory virus vaccine (in addition to influenza, COVID-19, and pneumococcal),” and challenges adding new vaccines.
“Facilities have had limited time to train providers to implement a shared clinical decision-making recommendation and develop processes and policies to support RSV vaccine administration. Nursing home staff members might also be less familiar with the risk for RSV outbreaks and severe disease among residents,” they said. “Increasing awareness of RSV as a cause of disease among nursing home residents might facilitate increased coverage.”
Adult Uptake
A minority of all adults in America have received one of the new COVID-19 vaccines, according to another paper published by the same journal on Thursday.Just 18.3 percent of adults have reported through Dec. 9 in surveys taking one of the shots, according to the paper.
Outside surveys show that many Americans did not intend to receive one of the new shots over concerns about side effects and a dearth of data supporting their usage.
The U.S. Food and Drug Administration cleared the shots earlier this year, and the CDC recommended them for virtually all Americans, despite there being clinical study data available for just one out of the three vaccines. Antibody levels from 50 people who received Moderna’s new vaccine were reported by the manufacturer.
Only animal data was cited for authorizing and recommending vaccines from Pfizer and Novavax.
The shots are reformulated each year to try to target the prevalent strains.
The CDC recommends all Americans aged 6 months and older get an influenza shot on an annual basis, unless they have a contraindication.
Per the survey data, just 17 percent of adults aged 60 or older have received an RSV vaccine.
The authors of the paper, all of whom work for the CDC, said that vaccination coverage could increase if health care providers recommend the shots to patients. They noted that the CDC is running advertisements to try to increase vaccination.
The CDC also issued an alert this month describing vaccination rates as low and calling for doctors to administer vaccines “now.”
Some doctors have said that the vaccines aren’t necessary, noting their low or unproven effectiveness and the risk of side effects.
“I am not recommending COVID-19 XBB.1.5 boosters, influenza, or respiratory syncytial virus vaccines for healthy adults or children,“ Dr. Peter McCullough wrote on Substack recently. ”None of these vaccines are compelling and conditions are easily treatable.”
Limitations of the new papers include the reliance on self-reporting by facilities or surveys. Authors did not disclose any potential conflicts of interest.
